G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023
Source: marketscreener.com